I. Bondarenko

发表

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.

K. O'Byrne, R. Ramlau, J. von Pawel, 2011, The Lancet. Oncology.

Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial

E. Mittendorf, I. Bondarenko, G. Peoples, 2019, Clinical Cancer Research.

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study

I. Bondarenko, H. Iwase, E. Tan-chiu, 2018, British Journal of Cancer.

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.

A. Oza, I. Bondarenko, N. Colombo, 2022, The Lancet. Oncology.

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy

I. Bondarenko, S. Tjulandin, M. Šmakal, 2019, BMC Cancer.

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

S. Loi, H. Iwata, A. DeMichele, 2016, The Lancet. Oncology.

Abstract P4-22-02: Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) withBRCA1orBRCA2mutations and metastatic breast cancer

A. Jager, M. Robson, M. Friedlander, 2017 .

Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer

M. Socinski, I. Bondarenko, C. Waller, 2021, Therapeutic advances in medical oncology.

Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies

I. Bondarenko, P. Bias, A. Buchner, 2015, Supportive Care in Cancer.

Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study

R. Kaiser, S. Novello, M. Krzakowski, 2017, Targeted Oncology.

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer

D. Gerber, I. Bondarenko, W. Su, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.

E. Perez, I. Bondarenko, A. Brufsky, 2009 .

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.

P. Zinzani, I. Bondarenko, Tongyu Lin, 2021, The Lancet. Oncology.

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer

P. Neven, M. Campone, D. Hayes, 2016, Clinical Cancer Research.

TUBULIN ROLE IN CANCER DEVELOPMENT AND TREATMENT

I. Bondarenko, Dolhyi, D. Avierin, 2019, Asploro Journal of Biomedical and Clinical Case Reports.

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Sung-Bae Kim, I. Bondarenko, C. Barrios, 2021, Breast Cancer Research and Treatment.

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study

E. Tokunaga, I. Bondarenko, O. Lipatov, 2022, BioDrugs.

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

H. Rugo, A. Manikhas, I. Bondarenko, 2021, Breast Cancer Research and Treatment.

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

S. Loi, H. Iwata, A. DeMichele, 2018, The New England journal of medicine.

Milestones over the development of SB3, a trastuzumab biosimilar.

I. Bondarenko, X. Pivot, E. Curtit, 2018, Future oncology.

Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

R. Finn, Marcus Schmidt, I. Bondarenko, 2014 .

Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab

I. Bondarenko, L. Hart, D. Spigel, 2019, Annals of Oncology.

Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18).

R. Finn, Marcus Schmidt, I. Bondarenko, 2017 .

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

T. Lynch, I. Bondarenko, F. Barlesi, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.

D. Miles, D. Cameron, J. Canon, 2017, European journal of cancer.

Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial.

R. Kaiser, S. Novello, M. Krzakowski, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.

H. Wildiers, Yeon-Hee Park, M. Friedlander, 2020, The Lancet. Oncology.

Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane

S. Krishnamurthy, M. Aapro, M. Campone, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Justification effectiveness of systemic treatment of breast cancer depending on body mass index

I. Bondarenko, V. Zavizion, M. HojoujMohammadI, 2017 .

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

K. Wilner, R. Finn, Marcus Schmidt, 2020, Breast Cancer Research and Treatment.

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

I. Bondarenko, C. Ivanescu, V. Mastey, 2022, Cancer.

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

W. Gradishar, J. Garber, A. Jager, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer

H. Wildiers, Yeon-Hee Park, M. Friedlander, 2019, Annals of Oncology.

Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients

A. Lammerich, I. Bondarenko, O. Gladkov, 2016, Supportive Care in Cancer.

Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy

I. Bondarenko, O. Gladkov, P. Bias, 2015, SpringerPlus.

Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy.

I. Bondarenko, O. Gladkov, N. Avisar, 2014, Clinical breast cancer.

Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy

I. Bondarenko, O. Gladkov, P. Bias, 2013, BMC Cancer.

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.

N. Reinmuth, Haiyi Jiang, N. Byrne, 2020, Journal of Clinical Oncology.

Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).

P. Neven, M. Campone, D. Hayes, 2014 .

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Xin Huang, Johannes Ettl, Marcus Schmidt, 2015, The Lancet. Oncology.

Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

E. Ette, I. Bondarenko, Yanqiu Zhao, 2020, JAMA oncology.

Use of modified McMaster method for the diagnosis of intestinal helminth infections and estimating parasitic egg load in human faecal samples in non-endemic areas

I. Bondarenko, M. Kuchta, A. Konigova, 2009, Helminthologia.

Antioxidant therapy as a protector and corrector of haematological toxicity of systemic therapy for breast cancer

I. Bondarenko, N. Bukhtiyarova, A. Prokhach, 2016 .

Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

S. Loi, H. Rugo, H. Iwata, 2021 .

A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous non-small cell lung cancer (sqNSCLC) previously treated with platinum-based chemotherapy.

G. Scagliotti, R. Govindan, I. Bondarenko, 2016 .

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

Rolf Kaiser, Birgit Gaschler-Markefski, Jean-Yves Douillard, 2014, The Lancet. Oncology.

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

T. Mok, I. Bondarenko, B. Karaszewska, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.

A. Oza, I. Bondarenko, N. Colombo, 2021 .

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

J. Neal, T. Lynch, I. Bondarenko, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

I. Bondarenko, L. Hart, J. Goldschmidt, 2020, International journal of cancer.

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

G. Scagliotti, S. Novello, I. Bondarenko, 2014, BMC Cancer.

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.

G. Scagliotti, J. Milanowski, F. Shepherd, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.

Melissa L. Johnson, L. Byers, A. Navarro, 2021, Clinical lung cancer.

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

H. Rugo, A. Manikhas, I. Bondarenko, 2021, Breast.

A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer.

I. Bondarenko, M. Reck, N. Kovalenko, 2020, Lung Cancer.

PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

N. Reinmuth, I. Bondarenko, K. Syrigos, 2019, BioDrugs.

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer: A Randomized Clinical Trial

H. Rugo, A. Manikhas, I. Bondarenko, 2017, JAMA.

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

R. Finn, Marcus Schmidt, I. Bondarenko, 2016, Breast Cancer Research.

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

N. Reinmuth, Haiyi Jiang, N. Byrne, 2020, The Lancet. Oncology.

ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155).

A. Oza, R. Wenham, H. Gabra, 2018 .

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

R. Greil, J. Bergh, K. Kern, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

N. Reinmuth, Y. Shrestha, Yuh-Min Chen, 2020 .

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

S. Loi, H. Rugo, H. Iwata, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study

E. Tokunaga, I. Bondarenko, O. Lipatov, 2022, BioDrugs.

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer†

P. Neven, M. Campone, D. Hayes, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.

Sung-Bae Kim, L. Carey, R. Bose, 2016, JAMA oncology.

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.

R. Epstein, M. Campone, I. Bondarenko, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Global clinical trials validating bioequivalence with China-manufactured trastuzumab biosimilar, HLX02, and trastuzumab.

I. Bondarenko, A. Luk, W. Li, 2018, Annals of Oncology.

Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial

Bing-he Xu, I. Bondarenko, Wei Li, 2021, BioDrugs.

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

M. Ellis, J. Robertson, A. Manikhas, 2016, The Lancet.

Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane

P. Fasching, Sung-Bae Kim, M. Piccart, 2021 .

First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer

Bing-he Xu, I. Bondarenko, Q. Wang, 2019, Annals of Oncology.

LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC

H. Wakelee, N. Altorki, I. Bondarenko, 2021, Annals of Oncology.

FP04.03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

N. Rizvi, I. Lowy, I. Bondarenko, 2021, Journal of Thoracic Oncology.

Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study.

N. Reinmuth, I. Bondarenko, I. Vynnychenko, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin

H. Rugo, A. Manikhas, I. Bondarenko, 2017 .

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.

E. Van Cutsem, J. Tabernero, M. Fakih, 2023, Journal of Clinical Oncology.

Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.

Rolf Kaiser, Birgit Gaschler-Markefski, Jean-Yves Douillard, 2015, European journal of cancer.

Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2‒) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies.

H. Rugo, S. Verma, R. Finn, 2018 .

A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC

I. Bondarenko, M. Reck, N. Kovalenko, 2019, Annals of Oncology.

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study

I. Bondarenko, H. Iwase, E. Tan-chiu, 2018, British Journal of Cancer.

The characteristics of side effects of different modes of chemotherapy for breast cancer.

I. Bondarenko, A. V. Phokhach, 2016 .

Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.

Ying Cheng, R. Kaiser, J. von Pawel, 2015, Lung cancer.

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.

R. Epstein, M. Campone, I. Bondarenko, 2012 .

Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.

I. Bondarenko, M. Schuler, J. Yang, 2012 .

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

A. Schneeweiss, D. Miles, F. Puglisi, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer

I. Bondarenko, P. Bycott, A. Ingrosso, 2015, BMC Cancer.

1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)

D. Miles, D. Cameron, J. Canon, 2015 .

LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

B. Monk, D. Berton, I. Bondarenko, 2020, Annals of Oncology.

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

A. Gasbarrini, W. Li, H. Harputluoglu, 2023, The Lancet.

ARIEL4: An international, multicenter randomized phase 3 study of the PARP inhibitor rucaparib vs chemotherapy in germline or somatic BRCA1- or BRCA2-mutated, relapsed, high-grade ovarian carcinoma.

A. Oza, E. Swisher, I. Bondarenko, 2017 .

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.

A. Schneeweiss, D. Miles, M. Campone, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

C. Bokemeyer, I. Bondarenko, I. Çelik, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study.

K. O'Byrne, I. Bondarenko, C. Barrios, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

R. Kaiser, S. Novello, M. Krzakowski, 2014, The Lancet. Oncology.

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

I. Bondarenko, R. Gralla, I. Bondarenko, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

H. Rugo, M. Aapro, I. Bondarenko, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study

N. Reinmuth, N. Shire, Haiyi Jiang, 2019, Journal of Thoracic Oncology.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

I. Lowy, I. Bondarenko, M. Schenker, 2023, The Lancet Oncology.

Efficacy and safety of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy.

I. Bondarenko, O. Gladkov, P. Bias, 2012 .

Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting.

H. Rugo, G. Lyman, G. Curigliano, 2020 .

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

R. Kaiser, S. Novello, M. Krzakowski, 2014, The Lancet. Oncology.

LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%

N. Rizvi, I. Lowy, I. Bondarenko, 2020 .

Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).

P. Neven, M. Campone, D. Hayes, 2014 .

669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study

T. Powles, E. Plimack, B. Melichar, 2021, Annals of Oncology.

Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).

T. Lynch, I. Bondarenko, F. Barlesi, 2010 .

A randomized phase II study of axitinib in combination with pemetrexed/cisplatin (pem/cis) as first-line therapy for nonsquamous non-small cell lung cancer (NSCLC).

G. Scagliotti, I. Bondarenko, N. Yamamoto, 2012 .